Table 5.
OMERCT-OARSI responder index by visit
| Visit | Responders/non-responders | HD-hBO (N = 55) | MD-hBO (N = 53) | LD-hBO (N = 60) | Placebo (N = 55) |
|---|---|---|---|---|---|
| Visit 2 (day 14) | Responders | 10 (18.2%) | 8 (15.1%) | 8 (13.3%) | 7 (12.7%) |
| Non-responders | 45 (81.8%) | 45 (84.9%) | 52 (86.7%) | 48 (87.3%) | |
| Visit 3 (day 28) | Responders | 26 (47.3%) | 32 (60.4%) | 30 (50.0%) | 19 (34.6%) |
| Non-responders | 29 (52.7%) | 21 (39.6%) | 30 (50.0%) | 36 (65.5%) | |
| Visit 4 (day 56) | Responders | 46 (83.6%) | 43 (81.1%) | 46 (76.7%) | 6 (10.9%) |
| Non-responders | 9 (16.4%) | 10 (18.9%) | 14 (23.3%) | 49 (89.1%) | |
| p value | < 0.0001 | < 0.0001 | < 0.0001 |
p value: day 56 difference between the distribution of OMERACT-OARSI responders (N [% of total]) in each hBO group vs. the distribution of responders in the placebo group (chi square test)